---
title: "Correction: Remdesivir‑bisPropionate study — amendments to methods and Fig 6"
id: "plos-one-0-correction-remdesivir-bispropionate-a-better-derivative-of-remdesivir-against"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-0-correction-remdesivir-bispropionate-a-better-derivative-of-remdesivir-against"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020"
published_at: "2026-09-22T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Correction: Remdesivir‑bisPropionate study — amendments to methods and Fig 6
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-0-correction-remdesivir-bispropionate-a-better-derivative-of-remdesivir-against
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020)
- **Published At:** 2026-09-22T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This is a formal correction to the PLOS ONE article reporting on **Remdesivir‑bisPropionate (RDV‑bP)** and its comparative in vitro and in vivo PK/PD and therapeutic potential. - Publication details: correction published September 22, 2026, DOI 10.1371/journal.pone.0359020; the correction pertains to the original article cited in the notice. - In the Materials and Methods (III: In Vivo study for Therapeutic potential of RDV‑bP against SARS virus, toxicity and stability in vivo), the phrase “Route of Administration (Table 1)” should have been removed; the correction clarifies that this phrase was erroneous. - A specific sentence in the Sublingual administration subsection (Administration of test articles) contained an error; the corrected sentence is provided verbatim: “NV − −387, NV–387-RDV-bP-and placebo for the gummy preparations were administered as a paste and painting the inner cavity of mouth by the use of a tuberculin syringe with no needle as per schedule and quantities in Table 1.” - There was a labeling error in Figure 6 of the original publication. The correction supplies the correct Figure 6 (with downloadable PNG and TIFF) and reproduces the figure legend. - The Figure 6 legend reports an antiviral efficacy experiment: survival of male and female rats infected with NL‑63 SARS virus and treated with **NV387**, **NV387‑RDV**, **NV387‑RDV‑bP**, and **RDV‑SBECD (GLD)**. Values are mean ± SD from three experiments; statistical analyses used two independent experiments done in duplicate. Reported significance markers in the legend are *: p < 0.5; **: p < 0.1; ***: p < 0.05 (as listed in the correction). - The correction lists the reference to the original article (Chakraborty et al., PLoS One. 2026;21(2):e0324811) and notes this correction is open access under the Creative Commons Attribution License. - The notice does not provide additional experimental data, study results beyond the corrected figure label and methods phrasing, nor any new recommendations; it limits changes to wording and the corrected figure and legend as stated.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosone%2Farticle%3Fid%3D10.1371%2Fjournal.pone.0359020) * * About * Browse * Publish * [](https://journals.plos.org/plosone/ "PLOS One") * Search [advanced search](https://journals.plos.org/plosone/search) * [Browse Topics](https://journals.plos.org/plosone/subjectAreaBrowse) Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click [here](https://github.com/PLOS/plos-thesaurus/blob/master/README.md "Link opens in new window"). [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020) [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020) * Loading metrics Open Access Correction # Correction: Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of _in vitro_ and _in vivo_ PK/PD Study as well as its therapeutic potential * Ashok Chakraborty, * Anil Diwan, * Vijetha Chiniga, * Vinod Arora, * Yogesh Thakur, * Jayant Tatake, * Rajesh Pandey, * Preetam Holkar, * Neelam Holkar # Correction: Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of _in vitro_ and _in vivo_ PK/PD Study as well as its therapeutic potential * Ashok Chakraborty, * Anil Diwan, * Vijetha Chiniga, * Vinod Arora, * Yogesh Thakur, * Jayant Tatake, * Rajesh Pandey, * Preetam Holkar, … * Neelam Holkar ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: September 22, 2026 * * [Article](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020) * [Metrics](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0359020) * [Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0359020) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pone.0359020) * [Reference](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020#reference) * [Reader Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0359020) * [Figures](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020) In III: In Vivo study for Therapeutic potential of RDV-bP against SARS virus, toxicity and stability in vivo subsection of the Materials and Methods, the phrase “Route of Administration (Table 1)” should have been removed. In III: In Vivo study for Therapeutic potential of RDV-bP against SARS virus, toxicity and stability in vivo subsection of the Materials and Methods, there is an error in the first sentence of the Sublingual paragraph of the bulleted point Administration of test articles. The correct sentence is: NV − −387, NV–387-RDV-bP-and placebo for the gummy preparations were administered as a paste and painting the inner cavity of mouth by the use of a tuberculin syringe with no needle as per schedule and quantities in Table 1. There is a labelling error in Fig 6. Please see the correct Fig 6 here. [![thumbnail](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0359020.g006)](https://journals.plos.org/plosone/article/figure/image?size=medium&id=10.1371/journal.pone.0359020.g006 "Click for larger image") Download: * [PNG larger image](https://journals.plos.org/plosone/article/figure/image?download&size=large&id=10.1371/journal.pone.0359020.g006) * [TIFF original image](https://journals.plos.org/plosone/article/figure/image?download&size=original&id=10.1371/journal.pone.0359020.g006) Fig 6. Antiviral Efficacy of RDV-bP on NL63-Infected Rats: Survival of Male and Female rats infected with NL-63 SARS virus and treated with NV387, NV387-RDV, NV387-RDV-bP and RDV-SBECD (GLD). Values are the mean ± SD from 3 experiments. Statistical analyses were done from two independent experiments done in duplicate. *: p < 0.5; **: p < 0.1; ***: p < 0.05. [ https://doi.org/10.1371/journal.pone.0359020.g006](https://doi.org/10.1371/journal.pone.0359020.g006) ## Reference 1. 1. Chakraborty A, Diwan A, Chiniga V, Arora V, Thakur Y, Tatake J, et al. Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of _in vitro_ and _in vivo_ PK/PD Study as well as its therapeutic potential. PLoS One. 2026;21(2):e0324811. pmid:41719342 * [ View Article ](https://doi.org/10.1371/journal.pone.0324811 "Go to article") * [ PubMed/NCBI ](http://www.ncbi.nlm.nih.gov/pubmed/41719342 "Go to article in PubMed") * [ Google Scholar ](http://scholar.google.com/scholar?q=Remdesivir-bisPropionate%2C+a+better+derivative+of+remdesivir+against+SARS-CoV-2%3A+Comparison+of+in+vitro+and+in+vivo+PK%2FPD+Study+as+well+as+its+therapeutic+potential+Chakraborty+2026 "Go to article in Google Scholar") ## Figures ![Fig 6](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0359020.g006) ![Fig 6](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0359020.g006) ![Fig 6](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0359020.g006) **Citation:** Chakraborty A, Diwan A, Chiniga V, Arora V, Thakur Y, Tatake J, et al. (2026) Correction: Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of _in vitro_ and _in vivo_ PK/PD Study as well as its therapeutic potential. PLoS One 21(9): e0359020. https://doi.org/10.1371/journal.pone.0359020 **Published:** September 22, 2026 **Copyright:** © 2026 Chakraborty et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. [Download PDF](https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0359020&type=printable) * [Citation](https://journals.plos.org/plosone/article/citation?id=10.1371/journal.pone.0359020) * [XML](https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0359020&type=manuscript) [Print](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0359020) Share * [![Reddit](https://journals.plos.org/resource/img/icon.reddit.16.png)Reddit](https://www.reddit.com/submit?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0359020 "Submit to Reddit") * [![Facebook](https://journals.plos.org/resource/img/icon.fb.16.png)Facebook](https://www.facebook.com/share.php?u=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0359020&t=Correction:%20Remdesivir-bisPropionate,%20a%20better%20derivative%20of%20remdesivir%20against%20SARS-CoV-2:%20Comparison%20of%20in%20vitro%20and%20in%20vivo%20PK/PD%20Study%20as%20well%20as%20its%20therapeutic%20potential "Share on Facebook") * [![LinkedIn](https://journals.plos.org/resource/img/icon.linkedin.16.png)LinkedIn](https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0359020&title=Correction:%20Remdesivir-bisPropionate,%20a%20better%20derivative%20of%20remdesivir%20against%20SARS-CoV-2:%20Comparison%20of%20in%20vitro%20and%20in%20vivo%20PK/PD%20Study%20as%20well%20as%20its%20therapeutic%20potential&summary=Checkout%20this%20article%20I%20found%20at%20PLOS "Add to LinkedIn") * [![Mendeley](https://journals.plos.org/resource/img/icon.mendeley.16.png)Mendeley](https://www.mendeley.com/import/?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0359020 "Add to Mendeley") * [![Bluesky](https://journals.plos.org/resource/img/icon.bluesky.light.png)Bluesky](https://bsky.app/intent/compose?text=Checkout%20this%20article%20I%20found%20at%20PLOS:%20https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0359020 "Share on Bluesky") * ![Email](https://journals.plos.org/resource/img/icon.email.16.png)Email ![Check for updates via CrossMark](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_BW_horizontal.svg) ### Related PLOS Articles * **CORRECTION pertains to** * Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of _in vitro_ and _in vivo_ PK/PD Study as well as its therapeutic potential * [View Page](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0324811) * [PDF](https://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0324811 "PDF opens in new window") Advertisement * [Publications](https://plos.org/our-journals/) * [PLOS Aging and Health](https://journals.plos.org/agingandhealth/) * [PLOS Biology](https://journals.plos.org/plosbiology/) * [PLOS Climate](https://journals.plos.org/climate/) * [PLOS Complex Systems](https://journals.plos.org/complexsystems/) * [PLOS Computational Biology](https://journals.plos.org/ploscompbiol/) * [PLOS Digital Health](https://journals.plos.org/digitalhealth/) * [PLOS Ecosystems](https://journals.plos.org/ecosystems/) * [PLOS Genetics](https://journals.plos.org/plosgenetics/) * [PLOS Global Public Health](https://journals.plos.org/globalpublichealth/) * [PLOS Medicine](https://journals.plos.org/plosmedicine/) * [PLOS Mental Health](https://journals.plos.org/mentalhealth/) * [PLOS Neglected Tropical Diseases](https://journals.plos.org/plosntds/) * [PLOS One](https://journals.plos.org/plosone/) * [PLOS Pathogens](https://journals.plos.org/plospathogens/) * [PLOS Sustainability and Transformation](https://journals.plos.org/sustainabilitytransformation/) * [PLOS Water](https://journals.plos.org/water/) * [Home](https://plos.org) * [Blogs](https://blogs.plos.org) * [Collections](https://collections.plos.org/) * Give feedback * [LOCKSS](https://journals.plos.org/plosone/lockss-manifest) * [Privacy Policy](https://plos.org/privacy-policy) * [Terms of Use](https://plos.org/terms-of-use) * [Advertise](https://plos.org/advertise/) * [Media Inquiries](https://plos.org/media-inquiries) * [Contact](https://plos.org/contact) ![PLOS](https://journals.plos.org/resource/img/logo-plos-footer.png) PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in California, US ![PLOS Logo](data:image/svg+xml;charset=utf-8;base64,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) ### Cookie Preference Center Our website uses different types of cookies. Optional cookies will only be set with your consent and you may withdraw this consent at any time. Below you can learn more about the types of cookies PLOS uses and register your cookie preferences. Accept All Cookies ### Customize Your Cookie Preference +**Strictly Necessary** Always On +**Functional** OnOff +**Performance and Analytics** OnOff +**Marketing** OnOff Save Selected Preferences and Close [For more information about the cookies and other technologies used by us, please read our Cookie Policy.](https://plos.org/cookies-policy)
## Related Clinical Research

- [Bundibugyo virus infection treated with MBP134 monoclonal antibodies and remdesivir: a case report](https://medichelpline.com/clinical-feed/nature-0-a-case-of-bundibugyo-virus-disease-treated-with-monoclonal-antibodies-and.md)
- [NanoLuc-expressing Feline Calicivirus as a Reporter for Antibody Neutralisation and Antiviral Scre](https://medichelpline.com/clinical-feed/biorxiv-3-feline-calicivirus-encoding-nanoluc-luciferase-as-a-tool-for-assessing-antibody.md)
- [Bundibugyo Ebola outbreak reveals gaps in Ebola preparedness and need for pan-filovirus tools](https://medichelpline.com/clinical-feed/stat-news-1-opinion-we-prepared-for-ebola-but-not-this-ebola.md)
- [Ebola Preparedness: Addressing the Gap in Virus Species Research](https://medichelpline.com/clinical-feed/stat-news-9-opinion-we-prepared-for-ebola-but-not-this-ebola.md)
- [Phase 1 trials and PARTNERS platform target Bundibugyo Ebola strain](https://medichelpline.com/clinical-feed/medical-news-today-40-phase-1-trials-for-ebola-treatments-and-vaccines-offer-hope-say-experts.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.